Europe Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2021-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0322019

Publication Date:

March 31, 2022

Pages:

140

Publisher:

Grace 麻豆原创 Data

Countries:

Europe [1]

USD 2,900.00

Research & Development (Pharma & Healthcare) [2]

IT & eHealth [3]

Pharma & Healthcare [4]

Description:

Europe pharmaceutical contract research organization (CRO) market was valued at $12.13 billion in 2021 and will grow by 9.6% annually over 2021-2030, driven by the increasing incidence of disease, rising healthcare expenditures, increasing dependence on contract research organizations due to improved efficiency and productivity.
Highlighted with 69 tables and 48 figures, this 140-page report 鈥淓urope Pharmaceutical Contract Research Organization (CRO) 麻豆原创 2021-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity鈥� is based on comprehensive research of the entire Europe pharmaceutical contract research organization (CRO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2030 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical contract research organization (CRO) market in every aspect of the classification from perspectives of Service, Therapeutic Application, End User, and Country.

Based on Service, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
鈥� CRO for Pre-clinical Development
鈥� CRO for Phase I Trials
鈥� CRO for Phase II Trials
鈥� CRO for Phase III Trials
鈥� CRO for Phase IV Trials
鈥� Laboratory Services
鈥� Consulting Services
鈥� Data Management Services
Based on Therapeutic Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
鈥� Infectious Diseases
鈥� Oncology
鈥� Metabolic Disorders
鈥� Cardiovascular Disorders
鈥� Central Nervous System
鈥� Respiratory Disorders
鈥� Gastrointestinal Disorders
鈥� Other Therapeutic Applications

By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2021-2030 included in each section.
鈥� Pharmaceutical & Biopharmaceutical Companies
鈥� Medical Device Companies
鈥� Academic Institutes

Geographically, the following national/local markets are fully investigated:
鈥� Germany
鈥� UK
鈥� France
鈥� Spain
鈥� Italy
鈥� Russia
鈥� Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2021-2030. The breakdown of key national markets by Service, Therapeutic Application, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON Plc
IQVIA Holdings Inc.
LSK Europe Pharma Service Co., Ltd.
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co., Ltd.
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the 麻豆原创 23
2.2 Major Growth Drivers 25
2.3 麻豆原创 Restraints and Challenges 33
2.4 Emerging Opportunities and 麻豆原创 Trends 36
2.5 Porter鈥檚 Fiver Forces Analysis 40
3 Segmentation of Europe 麻豆原创 by Service 44
3.1 麻豆原创 Overview by Service 44
3.2 CRO for Pre-clinical Development 46
3.3 CRO for Phase I Trials 47
3.4 CRO for Phase II Trials 48
3.5 CRO for Phase III Trials 49
3.6 CRO for Phase IV Trials 50
3.7 Laboratory Services 51
3.8 Consulting Services 52
3.9 Data Management Services 53
4 Segmentation of Europe 麻豆原创 by Therapeutic Application 54
4.1 麻豆原创 Overview by Therapeutic Application 54
4.2 Infectious Diseases 56
4.3 Oncology 57
4.4 Metabolic Disorders 58
4.5 Cardiovascular Disorders 59
4.6 Central Nervous System 60
4.7 Respiratory Disorders 61
4.8 Gastrointestinal Disorders 62
4.9 Other Therapeutic Applications 63
5 Segmentation of Europe 麻豆原创 by End User 64
5.1 麻豆原创 Overview by End User 64
5.2 Pharmaceutical & Biopharmaceutical Companies 66
5.3 Medical Device Companies 67
5.4 Academic Institutes 68
6 European 麻豆原创 2019-2030 by Country 69
6.1 Overview of European 麻豆原创 69
6.2 Germany 72
6.3 UK 74
6.4 France 77
6.5 Spain 79
6.6 Italy 81
6.7 Russia 83
6.8 Rest of European 麻豆原创 85
7 Competitive Landscape 87
7.1 Overview of Key Vendors 87
7.2 New Product Launch, Partnership, Investment, and M&A 91
7.3 Company Profiles 92
Charles River Laboratories 92
CMIC Co. Ltd 94
Covance Inc. 96
Hangzhou Tigermed Consulting Co., Ltd. 100
ICON Plc 103
IQVIA Holdings Inc. 106
LSK Global Pharma Service Co., Ltd. 110
Novotech Pty Ltd 112
PAREXEL International Corporation 114
Pharmaceutical Product Development LLC (PPD) 118
PRA Health Sciences Inc. 120
Quanticate Ltd 122
Samsung Bioepis Co., Ltd. 124
SGS SA (SGS Life Sciences) 126
Syneos Health Inc. 129
WuXi AppTec Inc. 132
8 Investing in Europe 麻豆原创: Risk Assessment and Management 134
8.1 Risk Evaluation of Europe 麻豆原创 134
8.2 Critical Success Factors (CSFs) 137
Related Reports and Products 140

Companies Mentioned:

Selected Key Players:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co., Ltd.
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co., Ltd.
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co., Ltd.
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.